Galderma's Nemluvio Shows Long-Term Efficacy

Galderma announced new data from the OLYMPIA open-label extension study, demonstrating the long-term safety and efficacy of Nemluvio in treating moderate-to-severe prurigo nodularis. The results, to be presented at 2026 Winter Clinical Miami, showed that Nemluvio maintained disease control and a well-tolerated safety profile for up to three years, with significant improvements in itch intensity, skin lesions, and quality of life. Over 70% of patients achieved clear or almost clear skin lesions, and over 85% experienced clinically meaningful itch improvement. Nemluvio, initially developed by Chugai Pharmaceutical Co., is the first approved monoclonal antibody targeting IL-31 receptor alpha and is approved by multiple regulatory authorities, including the United States===Food and Drug Administration and the European Union, for prurigo nodularis and moderate-to-severe atopic dermatitis.